Biotech

All Articles

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings and...

Lykos are going to talk to FDA to reconsider its own selection complying with turndown of MDMA treatment for trauma

.Observing a poor presenting for Lykos Therapeutics' MDMA candidate for trauma at a latest FDA consu...

AN 2 fifty percents head count, quits phase 3 test after records disappoint

.AN2 Therapies is actually reviewing its own organization in feedback to uninspired midphase data, p...

Merck pays $700M for bispecific, spying autoimmune opening and also chance to test Amgen in cancer

.Merck &amp Co. is spending $700 million in advance to challenge Amgen in a blood stream cancer mark...

Gilead pays J&ampJ $320M to exit licensing deal for seladelpar

.Along With Gilead Sciences on the verge of an FDA selection for its own liver illness drug seladelp...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks can find the providers setting up camping tents at basecamp beh...

Entero giving up team, moving out of office and also stopping briefly R&ampD

.Mattress Liquidators has actually turned Entero Therapies white colored as a piece. The lender boug...

Exelixis loses ADC after determining it is actually no suit for Tivdak

.Exelixis is giving up on its tissue variable (TF)- targeting antibody-drug conjugate after wrapping...

Relay dislikes SHP2 inhibitor after Genentech leaves

.3 full weeks after Roche's Genentech device ignored an SHP2 inhibitor pact, Relay Therapeutics has ...

Stoke's Dravet syndrome med discharged of partial scientific grip

.Stoke Therapies' Dravet disorder medicine has actually been devoid of a predisposed grip, clearing ...